Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : Sirona Biochem Corp
Deal Size : Undisclosed
Deal Type : Partnership
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
Brand Name : TFC-039
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Sirona Biochem Corp
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Recipient : Regent Pacific
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application
Details : Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.
Brand Name : Senstend
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Lidocaine,Prilocaine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Recipient : Regent Pacific
Deal Size : $4.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
